pentobarbital will lower the level or impact of fosphenytoin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Check.

Stay clear of; coadministration with CYP3A inducers might lead to reduced plasma concentrations of elvitegravir and/or perhaps a concomitantly administered protease inhibitor and result in loss of therapeutic effect also to possible resistance

pentobarbital will lower the level or impact of bedaquiline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Stay away from coadministration of bedaquiline with robust CYP3A4 inducers resulting from potential for reduced therapeutic outcome

Contraindicated (one)pentobarbital will minimize the extent or effect of naloxegol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Usage of naloxegol with powerful CYP3A4 inducers is just not recommended

pentobarbital increases toxicity of buprenorphine, very long-performing injection by pharmacodynamic synergism. Modify Therapy/Keep an eye on Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants raises risk of adverse reactions which include overdose, respiratory despair, and Dying. Cessation of benzodiazepines or other CNS depressants is favored normally.

pentobarbital will lower the extent or outcome of oxybutynin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unfamiliar.

pentobarbital will lessen the extent or outcome of glecaprevir/pibrentasvir by influencing hepatic/intestinal enzyme CYP3A4 metabolism.

pentobarbital will minimize the extent or outcome of aripiprazole by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.

pentobarbital will minimize the extent or effect of estradiol vaginal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.

pentobarbital will lower the extent or impact of lumefantrine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with powerful CYP3A4 inducers may result in reduced serum concentrations and lack of antimalarial efficacy

pentobarbital will decrease the level or effect of bosentan by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Not known.

With therapeutic doses of TCAs, barbiturates boost metabolism and reduce blood concentrations of TCAs.

pentobarbital will decrease the extent or effect of bortezomib by check here impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.

benzhydrocodone/acetaminophen and pentobarbital both enhance sedation. Stay clear of or Use Alternate Drug. Limit use to sufferers for whom alternative remedy solutions are inadequate